- OraSure Technologies Inc OSUR has secured a $109 million contract from the U.S. Department of Defense to build additional manufacturing capacity in the U.S. for InteliSwab COVID-19 rapid tests.
- Related: OraSure Secures $13.6M BARDA Funding For InteliSwab COVID-19 Test 510(k) Clearance and CLIA Waiver.
- The federal funding will expand OraSure's production capacity by 100 million tests annually by March 2024.
- An existing OraSure location in Bethlehem, Pennsylvania, will be retrofitted to accommodate increased manufacturing, and an additional new facility will be added in another U.S. location.
- In addition to this contract, OraSure also has internally funded expansion plans to achieve 120 million tests annually by Q2 of 2022.
- Related: FDA Establishes Additional Conditions Of Emergency Use Nod For COVID-19 Tests For Viral Mutations.
- Price Action: OSUR stock is up 0.37% at $10.74 on the last check Monday.
OSUROraSure Technologies Inc
$3.031.00%
Edge Rankings
Momentum
16.09
Growth
28.49
Quality
-
Value
89.00
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
